Driven by favorable policies related to innovative drugs, unmet clinical needs, and increased pharmaceutical R&D expenditures, it is expected that the growth rate of innovative drugs in both global and Chinese pharmaceutical markets will exceed the average for generic drugs and the industry over the next few years, presenting a vibrant market for innovative drugs. Recombinant protein drugs are one of the important directions in new drug development and have a history of nearly 40 years. During this period, recombinant protein drugs have developed rapidly. The emergence of rice endosperm cell bioreactors has brought hope for solving problems such as low recombinant protein yields and difficulties in large-scale production. The rice endosperm cell expression system has become a potential new tool for efficient recombinant protein production.
For this reason, based on research into the market, Frost & Sullivan (Frost & Sullivan, abbreviated as "Frost & Sullivan") has released an independent research report titled "Plant-Based Protein Drug Market Industry Research Report".
The attachment is a condensed version of the report. If you want to obtain the full version or have further research needs on the plant-based protein drug market, please contact us:
Mr. Mao from Frost & Sullivan
Tel: (+86) 159-2139-6033
E-mail: fred.mao@frostchina.com
